Molecular determinants of response to neoadjuvant pembrolizumab plus chemotherapy in patients with high-risk, early-stage, triple-negative breast cancer: exploratory analysis of the open-label, multicohort phase 1b KEYNOTE-173 study

Molecular determinants of response to neoadjuvant pembrolizumab plus chemotherapy in patients with high-risk, early-stage, triple-negative breast cancer: exploratory analysis of the open-label, multicohort phase 1b KEYNOTE-173 study

Abstract Background The multicohort, open-label, phase 1b KEYNOTE-173 study was conducted to investigate pembrolizumab plus chemotherapy as neoadjuvant therapy for triple-negative breast cancer (TNBC). This exploratory analysis evaluated features of the tumor microenvironment that might be predictiv...

Full description

Saved in:
Bibliographic Details
Main Authors: Rebecca Dent, Javier Cortés, Yeon Hee Park, Eva Muñoz-Couselo, Sung-Bae Kim, Joohyuk Sohn, Seock-Ah Im, Esther Holgado, Theodoros Foukakis, Sherko Kümmel, Jennifer Yearley, Anran Wang, Michael Nebozhyn, Lingkang Huang, Razvan Cristescu, Petar Jelinic, Vassiliki Karantza, Peter Schmid
Format: Article
Language:English
Published: BMC 2025-03-01
Series:Breast Cancer Research
Subjects:
Immunohistochemistry
Triple-negative breast cancer
Tumor microenvironment
Online Access:https://doi.org/10.1186/s13058-024-01946-y
Tags: Add Tag
No Tags, Be the first to tag this record!

Internet

https://doi.org/10.1186/s13058-024-01946-y

Similar Items